A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.

Trial Profile

A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Tumour lysate particle-loaded dendritic cell vaccine Elios Therapeutics (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2016 to 1 Jun 2019.
    • 03 Feb 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Oct 2016 to 1 Jun 2018.
    • 21 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top